For children with sickle cell disease a stroke is probably the most devastating complication. Until recently the standard treatment was multiple blood transfusions. The logic behind this treatment is that these transfusions suppress the bone marrow of the recipient. As a result, the concentration of normal haemoglobin rises as the concentration of abnormal haemoglobin drops. In other words, the proportion of haemoglobin that is abnormal is reduced. As this happens, the risk of stroke declines. The risk of stroke can be predicted by means of Doppler ultrasound in the cranial vessels – flow rates return to normal as the proportion of normal haemoglobin in the blood increases.
However, people in low-income countries are often unwilling to undergo multiple transfusions. They cannot afford the time; transfusions are expensive; and there is a shortage of blood for people with acute emergencies, such as postpartum haemorrhage. However, there is another treatment for sickle cell disease called hydroxyurea. I was privileged to attend an inaugural lecture at the University of Ibadan given by the new professor of pediatrics, one Prof IkeOluwa Lagunju. She showed that this alternative treatment was just as good as multiple transfusions in improving blood flows in the cranial circulation. In an uncontrolled follow-up study she showed that the incidence of stroke in treated children was much lower than that predicted from the epidemiology.[1] That this purely medical treatment can improve blood flow to the same extent as multiple transfusions has subsequently been confirmed in a large, multi-centre randomised trial in high-income countries.
As you well know, I have an interest in the relevance of research in high-income countries for low-income countries and vice-versa.[2] I think this is a nice example of the growth in knowledge testing similar treatments across different contexts.
— Richard Lilford, CLAHRC WM Director
- Lagunju I, Brown BJ, Oyinlade AO, et al. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea. Pediatr Blood Cancer. 2018; 66(3): e27252.
- Lilford RJ. How Can Research in Low- and Middle-Income Countries (LMICs) Help People in High-Income Countries? NIHR CLAHRC West Midlands News Blog. 31 July 2015.